Paratek Pharmaceuticals, Inc.

Tufts College

Other

Polar Molecular Corp.

Dow Global Technolgoies LLC

Union Carbide Chemicals & Plastics Technology Corporation

Mark L Nelson

Darrell J Koza

Glen Robert Rennie

Mohamed Y Ismail

Roger Frechette

Beena Bhatia

Todd Bowser

Stuart B Levy

Peter Viski

Laura McIntyre

Michael P Draper

Laura Honeyman

Joel Berniac

Tadeusz Warchol

Otis L Nelson, Jr

Kwasi Ohemeng

Paul Hawkins

Paul Sheahan

Upul Keerthi Bandarage

David Messersmith

Atul K Verma

Jackson Chen

John Roberts Parrish

Jose Maria Fiandor

Araceli Mallo

Juan Carlos Cuevas

Karen Stapleton

Mark Grier

Haregewein Assefa

Carmen García-Luzón

Paul Abato

Laxma Reddy

Graham Jones

Faye Seyedi

Jingwen Pan

Oak K Kim

Ivan Jeremy Hartley

Paul Kevin Samples

Michael N Alekshun

Jeffrey Brian Drabish

Ivan Yanachkov

Gui Liu

Donald Alexander Morrow, Jr

Marcel Schaefer

Kim Dwight Powers

Jose Cavetano Jaen

Carlos Ray Morris

Alfred Richard Nelson

Tad Warchol

Jimmy Dumornay

N Laxma Reddy

Rachid Mechiche

Victor Amoo

Jeff Scott Levin

Mcintyre Laura

Oak Kim

Laura Mcintyre

Ted Warchol

Jude Mathews

Coordinated control systems and methods of controlling an actual process are provided. The coordinated control systems and methods of controlling an actual process utilize a nonlinear dynamic model, where measured disturbing variables are incorporated into the nonlinear dynamic model, and predictive controller calculations.

Gas phase polymerization process control using projected disturbance variables and nonlinear dynamic models

A method for modulating RNA with tetracycline compounds is described.

Methods of using substituted tetracycline compounds to modulate RNA

The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

9-aminomethyl substituted minocycline compounds

The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

4-dedimethylamino tetracycline compounds

A method for improving the prediction of polymer properties and a system having improved polymer property prediction capabilities is provided. The method for improving the prediction of polymer properties comprises: (1) providing a polymer; (2) providing a prediction model; (3) utilizing said prediction model to define an average polymer property prediction value; (4) determining a feasible range; (5) measuring one or more properties of said polymer; (6) determining whether said one or measured polymer properties are within said feasible range: (7) validating said one or more measured polymer properties if said one or more measured polymer properties fall within the feasible range or invalidating said one or more measured polymer properties if said one or more measured polymer properties fall outside of the feasible range; (8) optionally updating said prediction model; (9) repeating said previous steps at least one or more times; and (10) thereby improving the prediction of polymer properties.

Method for improving the prediction of polymer properties

The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

7-substituted tetracycline compounds

The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

3, 10, and 12a substituted tetracycline compounds

11,12-dehydrotetracycline compounds are described.

11a, 12-derivatives of tetracycline compounds

The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.

Substituted tetracycline compounds

Methods for using tetracycline compounds for the treatment of spinal muscular atrophy are described.

Methods for treating spinal muscular atrophy using tetracycline compounds

7-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted tetracycline compounds are described.

7-N-substituted phenyl tetracycline compounds

7-substituted fused ring tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted fused ring tetracycline compounds are described.

7-iodo tetracyclines and related methods

The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

9-substituted minocycline compounds

7, 8 and 9-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7, 8 and 9-substituted tetracycline compounds are described.

7, 8 and 9-substituted tetracycline compounds

Growing community of inventors

Norfolk, MA, United States of America

Mark L Nelson